Atrix, Elan partner
Atrix Laboratories Inc. (Nasdaq: ATRX), a Fort Collins-based pharmaceutical company, has formed a joint venture with Elan Corp. (NYSE: ELN) to advance the testing of a new pain product for cancer patients. Through their collaborative effort, Transmucosal Technology Ltd., the two companies have submitted a new drug application to the Food and Drug Administration for evaluating a transmucosal drug delivery technology in human clinical trials. Designed to provide rapid delivery of a potent opiate, the companies expect the technology to be used for quick relief or with compounds that are rapidly broken down in the body when taken orally.
SPONSORED CONTENT